key: cord-0747804-7591f5lz
authors: Mahapatra, Smita
title: SARS COV-2- IgG antibodies in blood donors in pandemic – a game changer for policy makers
date: 2021-10-13
journal: Transfus Clin Biol
DOI: 10.1016/j.tracli.2021.10.004
sha: 45c958ddb840e46f8ee2896fe34b292ba85d43b6
doc_id: 747804
cord_uid: 7591f5lz

Background: A novel beta coronavirus, named Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has been identified as the causative pathogen for the present pandemic. The objective of the study was to measure the levels of IgG antibodies targeting the SARS-CoV-2 during the peak period of the COVID-19 pandemic in Odisha State, India to know the magnitude of SARS-CoV-2 exposure, the prevalence of herd immunity in the population, the distribution of IgG-positive cases examined according to ABO blood groups and the number of blood donors with higher neutralizing IgG antibody titre who later on were converted into Plasma Donors donating Convalescent Plasma (CP). Method: This observational prospective study was conducted for a duration of three months on 1032 number of Blood donors consisting of 1025 number of males and 07 number of females. The samples of donors were subjected to Electro- chemiluminescence immunoassay (ECLIA) to detect SARS-CoV-2 IgG antibodies. Result: Out of 1032 Donors, 370(35.9%) were SARS-COV-2 IgG positive which included 303 donors (29.36%) with neutralizing antibody titre of SARS-COV2 IgG antibodies above 1:80. SARS-COV-2 IgG positive cases consisted of 367(35.8%) male and 3(42.9%) female donors. The number of IgG positive cases were highest in 21-40 years’ age group i.e. 323 out of 869(37.2%). In terms of Blood group, 145(42.4%) out of 342 were from B RhD positive group. Out of 22 donors who were positive with COVID 19 in the past with neutralizing IgG antibody titre more than 1:80, 6(27.3%) persons came for voluntary convalescent plasma(CP) donation. Conclusion: A high prevalence of SARS-CoV-2 antibodies was detected among blood donors which indicated a high level of exposure to the virus within the population and development of innate immunity against the virus. Policy makers can add the protocol of antibody testing in the screening of blood donors to enhance the number of Plasma Donation cases for the treatment of serious COVID patients.

in Wuhan, China, before spreading first within China and then globally. A novel beta coronavirus, named Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), was identified as the causative pathogen of this condition, which was later named coronavirus disease 2019 . This virus can be transmitted in humans by direct or indirect contact with respiratory droplets of an infected person 1 . Although the viral RNA has been detected in stool, blood and urine of COVID-19 patients, transmission via these routes have not yet been documented 2, 3 .It is not known whether COVID-19 can be transmitted by blood transfusion. Respiratory viruses have never been reported to be transmitted through blood or blood components; therefore, any potential risk of transmission by transfusion of blood collected from asymptomatic individuals is theoretical 4 . Infection with SARS-CoV-2 often presents with no symptom (asymptomatic) or mild symptoms like fever, dry cough, muscle pain, loss of taste, loss of smell etc and can even progress into severe forms of the illness and possible death especially in the elderly and/or persons living with other comorbidities 5, 6 . In India, the first case of COVID-19 was reported on January 30, 2020 8 . There is a wide variation in the reporting of cases across the States/Union Territories and across the districts within each State. The case reporting is based on the testing of individuals by Real-time reverse transcription-polymerase chain reaction (RT-PCR) and rapid antigen testing. But, the current testing criteria, which prioritize the allocation of testing capacity, can miss many asymptomatic, mild infections and previous, non-active viral infections. Therefore, serological tests might represent a useful method through which to investigate the prevalence of previous SARS-CoV-2 infections within the community can be determined and this would support the continued efforts to minimize the viral transmission rate and the design of sensible public health policies.

Antibodies to SARS-CoV-2 are produced by the adaptive immune system in response to virus exposure, at least in the vast majority of cases, serology based tests for SARS-CoV-2 may be used to determine the extent of asymptomatic SARS-CoV-2 infections and to monitor the COVID-19 pandemic.In this study, our objective was to measure the levels of IgG antibodies targeting the SARS-CoV-2 during the peak period of the COVID-19 pandemic in Odisha, India to know the magnitude of SARS-CoV-2 exposure & the prevalence of herd immunity in the population. Inaddition, the distribution of IgG-positive cases was examined according to ABO blood groups and the number of blood donors with higher neutralizing IgG antibody titre who later on were converted into Plasma Donors donating Convalescent Plasma (CP). Only those who gave consent to be tested for SARS-COV-2 IgG antibodies were included in the study. 6 . Those with Haemoglobin >12.5g/dl, platelet count>1,50,000 per microliter of blood and Total Leukocyte Count within normal limits were accepted. (Fig 4) 

The world is facing crisis and challenges with communities and economies everywhere affected by the COVID-19 pandemic. Seroepidemiological research study can help in the detection of asymptomatic or subclinical infections in the overall population. As SARS-CoV-2 is a novel virus, the surveillance of antibody seropositivity is likely to offer valuable information regarding the true magnitude of the infection. Social distancing and other public health measures are placing an increasing psychological burden on people, resulting in an increasing need for exit strategies 10 . COVID 19 is an acute respiratory disease whose specific treatment is still not established. One of the options in the treatment is Convalescent plasma (CP) therapy with required amount of neutralizing antibodies in the plasma of recovered COVID patients. In the present study, we systematically reviewed the seroprevalence of IgG antibody in healthy donors and tried to collect CP from the donors with neutralizing antibody titre more than 1: 80 from those who were willing to donate.

Though high levels of neutralizing antibodies were found in donors who donated under 60 days from diagnosis of COVID 19 11 , in our study we also found presence of IgG antibody in 361(35.74%) out of 1010 persons who were never affected with COVID in the past. This Since highest number of blood donors belonged to the age group 21-40 years, the seroprevalence was highest in this age group. However, recent study has correlated the increased vulnerability to infection with increasing age. The age-dependent pattern of disease severity has been well established; however, the underlying reasons for the differential spread of the virus among different age groups remain unclear 16 .

The prevalence of SARS-CoV-2 among blood donors can give an insight into the spread of the virus among healthy people, which can assist in the development of approaches designed to diminish transmission. But, few reports have been published in Medical literature on the incidence of SARS-CoV-2 among blood donors to date. Our results suggest the existence of a high prevalence of SARS-CoV-2 antibodies among the blood donors which may be due to wider circulation of the virus at the community level by the end of the first wave of the pandemic.

It is very important to recognize the incidence of SARS-CoV-2 infections among asymptomatic individuals as healthy people in epidemic regions may be similarly infected and remain asymptomatic, acting as major viral transmission reservoirs. Herd immunity is partially created with the extent of infection both with symptomatic as well as asymptomatic persons within a community 18 . Our study revealed high prevalence of SARS-CoV-2 seropositivity (35.9%) in comparison to those reported in other countries. Still, the value is much lesser than the required prevalence of 60%-70% level that has been proposed to be necessary for the establishment of herd immunity 19 .

In the present study, with much convincing,we could collect the neutralizing IgG antibody 

Persons donating blood are said to be healthy donors as they are thoroughly screened before being accepted for donation. The present study had high seroprevalence of SARS-CoV-2 antibodies among blood donors, higher with donors with female gender, 21-40 years' age group and blood group of B Rh D positive. In the present pandemic, the screening for antibodies against SARS-COV-2 can act as an indicator of the picture of the protection of the community against the novel virus. Policy makers can also add the protocol of antibody testing in the screening of blood donors. This is likely to act as an incentive and help enhance the number of Plasma Donation cases for the treatment of serious COVID patients.

A Review on SARS-CoV-2 Virology

Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore

Consistent detection of 2019 novel corona virus in saliva

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

First confirmed case of COVID-19 infection in India: A case report

10. Fiorillo, A, Gorwood, P. The consequences of the COVID-19 pandemic on mental health and implications for clinical practice

Constraints and challenges in convalescent plasma collection amidst the Covid 19 pandemic-strategies and recommendations to overcome these

Cluster of COVID-19 in northern France: A retrospective closed cohort study

Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors in Karachi, Pakistan. Transfusion and Apheresis Science

Gendered effects on inflammation reaction and outcome of COVID-19 patients in Wuhan

Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection

The association between ABO blood group and SARS-CoV-2 infection: A meta-analysis

Inhibition of the interaction between the SARS-CoV Spike protein and its cellular receptor by anti-histo-blood group antibodies

Substantial undocumented infection facilitates the rapid dissemination of novel corona virus (SARS-CoV-2)

Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination

Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat. Med of severe COVID-19: a propensity scorematched control study

Number of Blood Donors estimated for SARS-COV-2 IgG blood group wise